Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Journal: Frontiers in oncology
Published: March 04, 2022
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 20, 2021
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
Journal: Journal for immunotherapy of cancer
Published: July 11, 2021
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Journal: Frontiers in oncology
Published: April 16, 2021
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.
Journal: Cancer immunology research
Published: March 29, 2018
Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Journal: JCI insight
Published: November 21, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Journal: Cancer discovery
Published: August 11, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026